The tricuspid valve

Current perspective and evolving management of tricuspid regurgitation

Jason H Rogers, Steven F. Bolling

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Cardiovascular specialists have entered an era of renewed interest and enthusiasm surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percutaneous therapies for the treatment of aortic, pulmonic, and mitral valve disease. Despite this wave of investigation, little or no attention has been given to the treatment of tricuspid valve disease. Tricuspid regurgitation (TR) occurs mainly from tricuspid annular dilation, which can result from left-sided heart failure from myocardial or valvular causes, right ventricular volume and pressure overload, or dilation of cardiac chambers. If untreated at the time of surgical mitral valve repair, significant residual TR negatively impacts perioperative outcomes, functional class, and survival. TR does not reliably resolve after successful mitral valve surgery. If present at the time of mitral valve surgery, TR can usually be effectively addressed with ring annuloplasty. Because reoperations for recurrent TR carry high mortality rates, few patients are offered reoperation for redo tricuspid repair or replacement. As transcatheter therapies for mitral regurgitation arise, parallel percutaneous approaches for TR may be necessary. In this article, we review the anatomy, pathophysiology, and value of mechanical correction of TR, including potential transcatheter therapies for TR.

Original languageEnglish (US)
Pages (from-to)2718-2725
Number of pages8
JournalCirculation
Volume119
Issue number20
DOIs
StatePublished - May 26 2009

Fingerprint

Tricuspid Valve Insufficiency
Tricuspid Valve
Mitral Valve
Reoperation
Dilatation
Therapeutics
Heart Valve Diseases
Mitral Valve Insufficiency
Ventricular Pressure
Aortic Valve
Surgical Instruments
Anatomy
Heart Failure
Lung
Survival
Mortality

Keywords

  • Catheters
  • Surgery
  • Valve, tricuspid
  • Valves

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

The tricuspid valve : Current perspective and evolving management of tricuspid regurgitation. / Rogers, Jason H; Bolling, Steven F.

In: Circulation, Vol. 119, No. 20, 26.05.2009, p. 2718-2725.

Research output: Contribution to journalArticle

@article{3f0e24123fcc4b0ebf4c19dace8cc077,
title = "The tricuspid valve: Current perspective and evolving management of tricuspid regurgitation",
abstract = "Cardiovascular specialists have entered an era of renewed interest and enthusiasm surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percutaneous therapies for the treatment of aortic, pulmonic, and mitral valve disease. Despite this wave of investigation, little or no attention has been given to the treatment of tricuspid valve disease. Tricuspid regurgitation (TR) occurs mainly from tricuspid annular dilation, which can result from left-sided heart failure from myocardial or valvular causes, right ventricular volume and pressure overload, or dilation of cardiac chambers. If untreated at the time of surgical mitral valve repair, significant residual TR negatively impacts perioperative outcomes, functional class, and survival. TR does not reliably resolve after successful mitral valve surgery. If present at the time of mitral valve surgery, TR can usually be effectively addressed with ring annuloplasty. Because reoperations for recurrent TR carry high mortality rates, few patients are offered reoperation for redo tricuspid repair or replacement. As transcatheter therapies for mitral regurgitation arise, parallel percutaneous approaches for TR may be necessary. In this article, we review the anatomy, pathophysiology, and value of mechanical correction of TR, including potential transcatheter therapies for TR.",
keywords = "Catheters, Surgery, Valve, tricuspid, Valves",
author = "Rogers, {Jason H} and Bolling, {Steven F.}",
year = "2009",
month = "5",
day = "26",
doi = "10.1161/CIRCULATIONAHA.108.842773",
language = "English (US)",
volume = "119",
pages = "2718--2725",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - The tricuspid valve

T2 - Current perspective and evolving management of tricuspid regurgitation

AU - Rogers, Jason H

AU - Bolling, Steven F.

PY - 2009/5/26

Y1 - 2009/5/26

N2 - Cardiovascular specialists have entered an era of renewed interest and enthusiasm surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percutaneous therapies for the treatment of aortic, pulmonic, and mitral valve disease. Despite this wave of investigation, little or no attention has been given to the treatment of tricuspid valve disease. Tricuspid regurgitation (TR) occurs mainly from tricuspid annular dilation, which can result from left-sided heart failure from myocardial or valvular causes, right ventricular volume and pressure overload, or dilation of cardiac chambers. If untreated at the time of surgical mitral valve repair, significant residual TR negatively impacts perioperative outcomes, functional class, and survival. TR does not reliably resolve after successful mitral valve surgery. If present at the time of mitral valve surgery, TR can usually be effectively addressed with ring annuloplasty. Because reoperations for recurrent TR carry high mortality rates, few patients are offered reoperation for redo tricuspid repair or replacement. As transcatheter therapies for mitral regurgitation arise, parallel percutaneous approaches for TR may be necessary. In this article, we review the anatomy, pathophysiology, and value of mechanical correction of TR, including potential transcatheter therapies for TR.

AB - Cardiovascular specialists have entered an era of renewed interest and enthusiasm surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percutaneous therapies for the treatment of aortic, pulmonic, and mitral valve disease. Despite this wave of investigation, little or no attention has been given to the treatment of tricuspid valve disease. Tricuspid regurgitation (TR) occurs mainly from tricuspid annular dilation, which can result from left-sided heart failure from myocardial or valvular causes, right ventricular volume and pressure overload, or dilation of cardiac chambers. If untreated at the time of surgical mitral valve repair, significant residual TR negatively impacts perioperative outcomes, functional class, and survival. TR does not reliably resolve after successful mitral valve surgery. If present at the time of mitral valve surgery, TR can usually be effectively addressed with ring annuloplasty. Because reoperations for recurrent TR carry high mortality rates, few patients are offered reoperation for redo tricuspid repair or replacement. As transcatheter therapies for mitral regurgitation arise, parallel percutaneous approaches for TR may be necessary. In this article, we review the anatomy, pathophysiology, and value of mechanical correction of TR, including potential transcatheter therapies for TR.

KW - Catheters

KW - Surgery

KW - Valve, tricuspid

KW - Valves

UR - http://www.scopus.com/inward/record.url?scp=67449085333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449085333&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.108.842773

DO - 10.1161/CIRCULATIONAHA.108.842773

M3 - Article

VL - 119

SP - 2718

EP - 2725

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 20

ER -